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Detection of the HA-33 protein in botulinum
neurotoxin type G complex by mass spectrometry
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Abstract
Background: The disease botulism is caused by intoxication with botulinum neurotoxins (BoNTs), extremely toxic
proteins which cause paralysis. This neurotoxin is produced by some members of the Clostridium botulinum and
closely related species, and is produced as a protein complex consisting of the neurotoxin and neurotoxin-associated
proteins (NAPs). There are seven known serotypes of BoNT, A-G, and the composition of the NAPs can differ between
these serotypes. It was previously published that the BoNT/G complex consisted of BoNT/G, nontoxic-nonhemagglutinin
(NTNH), Hemagglutinin 70 (HA-70), and HA-17, but that HA-33, a component of the protein complex of other serotypes
of BoNT, was not found.
Methods: Components of the BoNT/G complex were first separated by SDS-PAGE, and bands corresponding to
components of the complex were digested and analyzed by LC-MS/MS.
Results: Gel bands were identified with sequence coverages of 91 % for BoNT/G, 91 % for NTNH, 89 % for HA-70,
and 88 % for HA-17. Notably, one gel band was also clearly identified as HA-33 with 93 % sequence coverage.
Conclusions: The BoNT/G complex consists of BoNT/G, NTNH, HA-70, HA-17, and HA-33. These proteins form the
progenitor form of BoNT/G, similar to all other HA positive progenitor toxin complexes.
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Background
Botulism is a disease which can be fatal if untreated and is
caused by intoxication with any of the extremely toxic
proteins known as botulinum neurotoxins (BoNTs).
BoNTs consist of a heavy chain, which binds to receptors
on the neuron, and a light chain which serves as a prote-
ase, cleaving proteins necessary for nerve signal transmis-
sion. This enzymatic cleavage leads to flaccid paralysis,
which can then lead to death if untreated. Botulinum
neurotoxins are currently classified into seven confirmed
serotypes, labeled A-G. BoNT/A, /C, and /E cleave SNAP-
25 (synaptosomal-associated protein) [1–6] whereas
BoNT/B, /D, /F, and /G cleave synaptobrevin-2 (also
known as VAMP-2) [7–12]. BoNT/C is also known to
cleave syntaxin [13, 14].
BoNTs are produced by Clostridum botulinum, C.
butyricum, C. baratii, and C. argentinese, and are
produced as a protein complex also known as the
progenitor toxin, consisting of the neurotoxin and
neurotoxin-associated proteins (NAPs). The composition
of this complex can differ between serotypes, and in
some cases, can differ within a serotype. For instance,
the complex of BoNT/A1 Hall strain is reported to con-
tain BoNT/A, NTNH, HA-70, HA-33, and HA-17 and
is therefore hemagglutinin positive [15, 16], whereas the
complex of BoNT/A2 is reported to contain only BoNT/
A and NTNH [17] as the hemagglutinin proteins are not
present, yet its genome contains open reading frames
encoding for three proteins with controversial existence
within the progenitor toxin [15, 17–19]. The role of
these NAPs has not been completely deduced; however,
it is likely that the NAPs serve to protect the progenitor
toxin from harsh conditions found in the stomach,
including low pH and digestive enzymes [20]. Addition-
ally, it has been proposed that these NAPs assist with
translocation of the neurotoxin across the intestinal epi-
thelium [21], and the NAPs may assist with the im-
munogenicity of BoNT/A [22].
Characterization of the composition of the progenitor
toxin of botulinum neurotoxins has been an area of
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abundant publication; however, characterization of the
progenitor toxin of BoNT/G has been minimal. In 1991, it
was reported that BoNT/G complex components sepa-
rated by SDS-PAGE into 6 bands, with molecular masses
of 150,000, 140,000, 58,000, 10,800, 10,600, and 10,400
[23]. Genetic analysis of the Clostridium botulinum type
G toxin complex revealed the presence of genes for the
neurotoxin, hemagglutinin, and nontoxin nonhemaggluti-
nin [24], with further analysis defining these components
as the neurotoxin, NTNH, HA-70, and HA-17 [25] and
later including HA-33 [26]. Protein characterization of the
progenitor complex of type G by mass spectrometry also
revealed the presence of BoNT/G, NTNH, HA-70, and
HA-17 [15, 27]. However, it was noted in the most recent
publication [27] that the identity of one of the gel bands
could not be determined. In this work, we show that the
identity of that gel band is the protein HA-33, with identi-
fication by mass spectrometry including sequence cover-
age of greater than 90 %.
Methods
Materials
Botulinum neurotoxin is highly toxic and requires appro-
priate safety measures. All neurotoxins were handled in a
class 2 biosafety cabinet equipped with HEPA filters.
Commercially purified BoNT/G complex toxin was pur-
chased (Metabiologics, Madison, WI). Sequencing-grade
modified trypsin at 0.5 mg/mL in 50 mM acetic acid and
sequencing grade chymotrypsin at 1 μg/μL in 50 mM am-
monium bicarbonate was purchased (Roche, Pleasanton,
CA). All chemicals were from Sigma-Aldrich (St. Louis,
MO) except where indicated.
Gel electrophoresis and digestion
SDS-PAGE gel electrophoresis was performed on a
NuPAGE Novex Bis-Tris gel using the manufacturer-
provided procedure (Invitrogen, Carlsbad, CA). Briefly,
1 μL of BoNT/G toxin complex at a concentration of
1 mg/mL was mixed with 2.5 μL of 4X sample buffer
and 6.5 μL of deionized water and heated to 70 °C for
10 min. The mixture was then loaded on a 4-12 % gradient
gel. The gel was stained with a Silver Stain kit (Protea Bio-
sciences, Morgantown, WV) following the manufacturer-
provided protocol. Selected gel bands containing visible
stained protein were sliced and were destained by adding
10 μL of the Protea silver destaining solution and incubat-
ing for 30 min at room temperature, so that each band was
fully destained. Each band was washed 3 times with 400 μL
of water and once with 400 μL of 50 mM ammonium bi-
carbonate and then the protein in each band was reduced
with 10 mM dithiothreitol at 60 °C for 30 min and alky-
lated with 55 mM iodoacetamide at room temperature in
the dark for 30 min. The in-gel digestion was performed in
20 μL of 50 mM ammonium bicarbonate containing 0.2 μg
of trypsin at 37 °C overnight. Following removal of the
liquid, the gel band was then digested in 20 μL of 50 mM
ammonium bicarbonate containing 0.2 μg of chymotrypsin
at 37 °C overnight.
LC-MS/MS analysis
NanoESI LC-MS/MS qualitative analysis was performed
on an LTQ-Orbitrap Elite mass spectrometer (Thermo
Scientific) connected to a nano-Acquity ultraperfor-
mance liquid chromatograph (UPLC; Waters, Milford,
MA). 4 μL of the protein digest was injected on a C18
column (100 μm x 100 mm, 1.7 μm, BEH130 Å) and the
peptides were separated using a linear gradient of 5-
35 % of buffer B (acetonitrile, 0.1 % formic acid) over
80 min at a flow rate of 0.5 μL/min. The data acquisition
was performed on an Xcalibur system using the data-
dependent mode where the 15 highest-intensity precursors
in an MS1 survey scan were isolated for collision-induced
dissociation. The resulting MS/MS data were searched for
protein candidates with a database search against an in-
house BoNT database using MASCOT software (Matrix
Sciences, London). The mass tolerance of precursor ions
and fragment ions was 10 ppm and 0.8 Da, respectively.
Resulting peptides were filtered with a significance thresh-
old of p < 0.05 and an ion score cutoff of 40. The peptides
with ion scores of less than 50 were validated by manual
inspection. Quantitative analysis was performed as previ-
ously described [28], spiking the digests with a yeast alcohol
dehydrogenase standard digest and using MSE on a Synapt
hybrid tandem mass spectrometer (Waters, Milford, MA).
Results
Separation of the BoNT/G complex by SDS-PAGE re-
sulted in the presence of several bands (Fig. 1). Seven of
the bands were excised, digested, and analyzed in a
qualitative fashion by LC-MS/MS to discern the identity
of the bands. The identities of the proteins in the gel are
listed in Table 1, with their NCBI accession numbers
and average masses. Band 1 was identified as BoNT/G
with 90.8 % sequence coverage. Band 2 was identified as
NTNH, also with 90.8 % sequence coverage. Band 3 was
identified as HA-70 with 89.2 % coverage as seen in
Fig. 2. It should be noted that the amino acid sequence
is different from the HA-70 protein sequence identified
in a previous publication [27].
Band 4 was identified as HA-70 as well, but only a C-
terminal portion consisting of approximately 2/3 of the
total protein (Fig. 2). Band 5 was identified as HA-33
with 92.6 % sequence coverage (Fig. 2). Band 6 was iden-
tified as HA-70, but only an N-terminal portion of ap-
proximately 1/3 of the total protein (Fig. 2). Band 7 was
identified as HA-17 with 87.8 % sequence coverage.
Bands in the 75–100 kDa region were identified as por-
tions of NTNH and BoNT/G and bands below 15 kDa
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were recognized as portions of HA-17 and NTNH.
Quantification of bands 3, 4, and 6 yielded a ratio of band
3: band 4: band 6 as 1:7:3, whereas quantification of bands
5 and 7 yielded a ratio of 5:1 of band 5 to band 7.
Discussion
The protein HA-33 is reported to exist as a part of the
progenitor toxin complex for some strains of BoNT/A,
/B, /C and /D [15]. In fact, the literature reports that for
every botulinum neurorotoxin which contains HA-70
and HA-17 as part of its toxin complex, HA-33 is also
present, with the exception of BoNT/G [15, 27]. There-
fore, it should not be surprising that HA-33 is also
present as part of the complex of BoNT/G, as we now
understand that in every BoNT complex where HA-70
and HA-17 are present, HA-33 is also present. It should
be noted that the gel separation in this work agreed with
gel separations previously published [27]. The gel band
which corresponds to HA-33 was previously reported as
unidentified due to the absence of identifiable peptides
following digestion and analysis [27]. Quantification of
the proteins in the BoNT/G progenitor toxin complex
shows that the amount of HA-33 is above the level of
HA-17, and HA-17 was previously identified as part of
the BoNT/G progenitor toxin complex, so it is likely
that HA-70 was not previously identified due to the use
of instrumentation with decreased sensitivity or the ab-
sence of HA-70 proteins from the database.
In this work, we also provide a longer amino acid se-
quence associated with the protein HA-70 than previ-
ously reported, giving this protein a molecular weight of
71742 Da. A previous report listed the identity of this
gel band as a protein with only 488 amino acids, and a
molecular weight of 55792 Da, likely due to the use of
older instrumentation and database. This longer amino
Table 1 Components of the progenitor BoNT/G toxin complex
Protein description Accession # Avg mass (kDa)
BoNT/G CA52275 149034
NTNH CA61228 139083
HA-70 YP001893656 71742
HA-33 WP039635745 32822
HA-17 CAA61226 17372
The proteins identified in the BoNT/G complex, NCBI accession numbers, and
average masses are listed
Fig. 1 Silver stained SDS-PAGE of separated protein toxin components
of BoNT/G. The first lane is molecular weight markers, the second lane
is blank, and the third lane is the separation of the components of the
BoNT/G complex. Seven bands as marked were excised, digested, and
analyzed by LC-MS/MS with identities determined of band 1 as BoNT/G,
band 2 as NTNH, band 3 as HA-70, band 4 as HA-70, band 5 as HA-33,
band 6 as HA-70, and band 7 as HA-17
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acid sequence more accurately reflects the identity of the
protein as the protein elutes on a gel with an approximate
molecular weight of 70 kDa. The amino acid sequence pre-
viously linked to this gel band only had a molecular weight
of 52716 Da [27]. Two additional gel bands contained
components of HA-70 with one composed of a C-terminal
portion of approximately 2/3 of the intact HA-70 protein
(Fig. 2) and the other an N-terminal portion of the
remaining approximately 1/3 of the intact HA-70 protein
(Fig. 2). Quantification of the bands shows that the most of
the HA-70 proteins is present as the processed form rather
than the intact form.
This phenomenon is not unusual and has been reported
for other progenitor complexes of BoNT; namely BoNT/A
and /C [15]. The progenitor toxins of both BoNT/A and
/C are reported to possess HAs with molecular weights of
approximately 52–55 kDa and 20 kDa respectively [16, 29],
and these HAs are reported as components originating
from the intact HA-70 gene product with proteolysis after
translation of the gene. Proteolysis of the intact HA-70
gene product in BoNT/A and /C is reported to occur
around amino acid 200, with the HA-52/55 protein com-
posed of the C-terminal portion of approximately 2/3 of
the intact protein and the HA-20 protein composed of the
N-terminal remainder. The proteolytic region of HA-70 is
not visible in the crystal structure of HA-70 of BoNT/A,
indicating that this region is exposed while complexed and
degraded due to proteolysis [30], and from these data here,
it is likely that the HA-70 of BoNT/G is similar. Addition-
ally, it should be noted that the data presented here were
obtained from purified toxin complex which may have a
different composition than toxin complex without
purification.
In addition to proteolysis of HA-70, there is also evi-
dence for limited proteolysis of other proteins. Bands
also appear in the gel in the region of 75–100 kDa and
10–15 kDa. Mass spectrometric amino acid sequencing
determined that these bands consisted of shorter ver-
sions of BoNT/G and NTNH in the 75–100 kDa region
and HA-17 and NTNH in the 10–15 kDa region. This
event is not original to BoNT/G, as our laboratory has
observed this process in gels of other BoNT (data not
shown), and this phenomenon has also been reported in
prior publications involving other HA positive BoNT
progenitor complexes [16, 31].
Conclusion
In conclusion, through this work, we have discovered that
the protein HA-33 is part of the BoNT/G progenitor toxin
complex, and therefore, the BoNT/G complex consists of
BoNT/G, NTNH, HA-70, HA-17, and HA-33. Thus, all
HA positive progenitor botulinum toxin complexes
known to date have the same composition. Additionally,
we have discovered that the amino acid sequence previ-
ously reported for the HA-70 protein of the BoNT/G
complex was incomplete due to the proteolytic processing
of the HA-70 protein. This proteolytic processing is con-
sistent with the proteolytic processing of HA-70 previ-
ously reported for other BoNT complexes.
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Fig. 2 Amino acid sequence and sequence coverages of selected identified components of the BoNT/G protein complex. Residues for which MS/
MS evidence exists are marked in red. a Band 3, identified as HA-70; b Band 4 identified as a C-terminal portion of HA-70; c Band 5 identified as
HA-33; and d Band 6 identified as an N-terminal portion of HA-70
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